A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Astellas Pharma Inc18 enrolled

Overview

The purpose of this study is to assess the safety, tolerability and antitumor activity of IMAB362 in Japanese subjects with locally advanced or metastatic Gastric or GEJ adenocarcinoma whose tumors have Claudin (CLDN) 18.2 Expression. This study will also assess pharmacokinetics and immunogenicity of IMAB362.

This study consists of two parts (Part 1: Safety; and Part 2: Expansion). First, the subjects will be enrolled in Safety Part with IMAB362 dose-1/2 (Arm A). Then the safety and tolerability of Arm A will be evaluated at Tolerability Evaluation Meeting (TEM). If there are no safety and tolerability concerns, enrollment for the Safety Part with IMAB362 dose-3 (Arm B) and the Expansion Part with IMAB362 dose-1/2 will be opened. For each part, participants who continue to derive clinical benefit and do not have intolerable toxicity from study treatment will be allowed to remain on treatment until treatment discontinuation criterion is met.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastric Cancer Gastro-esophageal Junction (GEJ) Cancer

Interventions

ZolbetuximabDRUG

Zolbetuximab will be administered as a 2-hour intravenous infusion.

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject has histologically or cytologically confirmed diagnosis of gastric or gastro-esophageal junction adenocarcinoma. * Subject has gastric or gastroesophageal junction (GEJ) adenocarcinoma based on radiographic imaging or endoscopic examination. * Subject agrees not to participate in another interventional study while on treatment. * Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Subject has predicted life expectancy ≥ 12 weeks. * Subject must have an available tumor specimen collected at any time prior to the first dose of study treatment. * Subject must meet all of the pre-specified criteria on the laboratory tests that will be analyzed locally within 7 days prior to the first dose of study drug. * Locally advanced or Metastatic gastric or GEJ adenocarcinoma with no standard of care treatment option or subject is ineligible to receive available standard of care treatment option. * Subject's tumor sample has Claudin (CLDN)18.2 membranous staining with any intensity as determined by central Immunohistochemistry (IHC) testing. (Safety part only) * Subject has CLDN18.2 high expression in ≥75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing. (Expansion Part Only) * Subject is an appropriate candidate for a tumor biopsy and is amenable to undergo a tumor biopsy during the Screening period and on-treatment tumor biopsy. (Expansion Part Only) * Subject has at least 1 measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 within 28 days prior to the first dose of study treatment. For subjects with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy. (Expansion Part Only) Exclusion Criteria: * Subject has prior severe allergic reaction or intolerance to a monoclonal antibody, including humanized or chimeric antibodies. * Subject has had radiotherapy within 2 weeks prior to first dose of study drug. Subject who received palliative radiotherapy to peripheral bone metastases within 2 weeks prior to first dose of study drug and has recovered from all acute toxicities is allowed. * Subject has received other investigational agents or devices concurrently or within 4 weeks prior first dose of study drug. * Subject has received systemic immunosuppressive therapy, including systemic corticosteroids 2 weeks prior to first dose of study drug. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent are allowed. * Subject has gastric outlet syndrome or persistent recurrent vomiting. * Subject has uncontrolled or significant gastrointestinal hemorrhage. * Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection. * Subject has a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (anti-HCV). Subjects who are negative for HBsAg, but hepatitis B core antibody (HBcAb) positive, hepatitis B virus deoxyribonucleic acid (DNA) test will be performed and if positive will be excluded. Subjects with positive serology but negative HCV ribonucleic acid (RNA) test results are eligible. * Subject has had within 6 months prior to first dose of study treatment any of the following: unstable angina, myocardial infarction, ventricular arrhythmia requiring intervention or hospitalization for heart failure * Subject has active infection requiring systemic therapy. * Subject has clinically significant other disease or co-morbidity, which may adversely affect the safe delivery of treatment within this trial. * Subject has psychiatric illness or social situations that would preclude study compliance. * Subject has active autoimmune disease that has required systemic immunosuppressive treatment in the past 2 years. * Subject has had a major surgical procedure within 28 days prior to the first dose of study drug. * Subject has Fridericia-corrected QT interval (QTcF) \> 450 msec for males and \> 470 msec for females on 12-lead electrocardiogram (ECG) at screening based on local testing. * Subject has any condition which makes the subject unsuitable for study participation. * Subject has another active malignancy which is likely to require treatment. * Subjects who find it difficult to adhere to the provisions of treatment and observation specified in the protocol.

Locations (1)

Site JP00001

Kashiwa, Chiba, Japan

Outcomes

Primary Outcomes

Dose Limiting Toxicities (DLT) in Safety Part

Any of the IMAB362 related AEs specified as the DLTs will be assessed during the first 3 weeks.

Time frame: Up to Day 22

Safety and tolerability assessed by incidence of adverse events (AEs) in Safety Part

An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) guidelines (Version 4.03).

Time frame: Up to 16 months

Number of participants with laboratory test abnormalities in Safety Part

Number of participants with potentially clinically significant laboratory values will be reported as AEs.

Time frame: Up to 14 months

Number of participants with body weight abnormalities in Safety Part

Number of participants with potentially clinically significant body weight change will be reported as AEs.

Time frame: Up to 14 months

Number of participants with vital sign abnormalities in Safety Part

Number of participants with potentially clinically significant vital sign values will be reported as AEs.

Time frame: Up to 14 months

Number of participants with 12-lead electrocardiogram (ECG) abnormalities in Safety Part

ECGs will be recorded with the participant in the supine position, after the subject has been lying down for approximately 5 minutes. Any clinically significant adverse changes on the ECG will be reported as AEs.

Time frame: Up to 14 months

Safety assessed by Eastern Cooperative Oncology Group (ECOG) performance status in Safety Part

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

ORR by local review in Safety Part

ORR is defined as the proportion of participants who have a best overall response of CR or PR per RECIST 1.1.

Time frame: Up to 13 months

ORR by central review in Expansion Part

ORR is defined as the proportion of participants who have a best overall response of CR or PR per RECIST 1.1.

Time frame: Up to 13 months

Disease Control Rate (DCR) in Safety Part and Expansion Part

DCR is defined as the proportion of participants who have a best overall response of CR, PR or stable disease (SD) per RECIST 1.1.

Time frame: Up to 13 months

Progression Free Survival (PFS) in Safety Part and Expansion Part

PFS is defined as the time from the date of first dosing until the date of radiological or clinical progressive disease per RECIST 1.1 or death from any cause, whichever is earliest.

Time frame: Up to 13 months

Overall Survival (OS) in Safety Part and Expansion Part

OS is defined as the time from the date of randomization until the date of death from any cause.

Time frame: Up to 23 months

Duration of Response (DOR) in Safety Part and Expansion Part

DOR is defined as the time from the date of the first response (CR or PR) per RECIST 1.1 to the date of radiological progression or death, whichever occurs earlier.

Time frame: Up to 13 months

Pharmacokinetics (PK) of IMAB362 in Safety Part and Expansion Part: Area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf)

AUCinf will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: Percentage of AUCinf (AUCinf (%extrap))

AUCinf (%extrap) will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: AUC from the time of dosing to the last measurable concentration (AUClast)

AUClast will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: AUC from the time of dosing to the start of the next dosing interval (AUCtau)

AUCtau will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: Maximum concentration (Cmax)

Cmax will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: Concentration immediately prior to dosing at multiple dosing (Ctrough)

Ctrough will be derived from the PK serum samples collected.

Time frame: Up to 16 months

PK of IMAB362 in Safety Part and Expansion Part: Time of the maximum concentration (tmax)

tmax will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: Terminal elimination half-life (t1/2)

t1/2 will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: Clearance (CL)

CL will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: Apparent volume of distribution at steady state (Vss)

Vss will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: Apparent volume of distribution during the terminal phase (Vz)

Vz will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: Accumulation ratio calculated using AUC (Rac(AUC))

Rac(AUC) will be derived from the PK serum samples collected.

Time frame: Up to 3 months

PK of IMAB362 in Safety Part and Expansion Part: Rac (Cmax)

Rac(Cmax) will be derived from the PK serum samples collected.

Time frame: Up to 3 months

Safety assessed by incidence of AEs in Expansion Part

Time frame: Up to 16 months

Number of participants with laboratory test abnormalities in Expansion Part

Number of participants with potentially clinically significant laboratory values will be reported as AEs.

Time frame: Up to 14 months

Number of participants with vital sign abnormalities in Expansion Part

Number of participants with potentially clinically significant vital sign values will be reported as AEs.

Time frame: Up to 14 months

Number of participants with body weight abnormalities in Expansion Part

Number of participants with potentially clinically significant body weight change will be reported as AEs.

Time frame: Up to 14 months

Number of participants with 12-lead ECG abnormalities in Expansion Part

ECGs will be recorded with the participant in the supine position, after the subject has been lying down for approximately 5 minutes. There should be at least 2 minutes between ECG measurements in case a repeat is needed. Any clinically significant adverse changes on the ECG will be reported as AEs.

Time frame: Up to 14 months

Safety assessed by ECOG performance status in Expansion Part

Number of participants with potentially clinically significant ECOG performance status values. ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.

Time frame: Up to 14 months

Frequency of anti-drug antibody (ADA)-positive participants in Safety Part and Expansion Part

Immunogenicity of IMAB362 will be assessed by the frequency of ADA-positive participants.

Time frame: Up to 16 months